Astellas Advances its Vaccine Ambitions with Affinivax’s Pneumococcal Candidate
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)
Published: 11 Mar-2017
DOI: 10.3833/pdr.v2017.i3.2231 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Looking to cutting-edge research to develop a global presence in vaccines, Astellas Pharma has in-licensed worldwide rights to a next-generation pneumococcal vaccine candidate from US-based start-up Affinivax for US$10 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS